![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: > Karnon Jonathan
Publisher: Adis International
ISSN: 1170-7690
Source: PharmacoEconomics, Vol.29, Iss.10, 2011-10, pp. : 823-825
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Trastuzumab reimbursement decisions not equitable
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 525, 2007-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
By Liberti Lawrence E. Pichler Franz Walker Stuart R.
Pharmaceutical Medicine, Vol. 23, Iss. 5-6, 2009-10 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Factors influencing Welsh reimbursement decisions analysed
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 660, 2012-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Addressing the challenge of type 2 diabetes
Inpharma, Vol. 1, Iss. 1248, 2000-01 ,pp. :